Share This Page
Suppliers and packagers for PAMELOR
✉ Email this page to a colleague
PAMELOR
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013 | NDA | SpecGx LLC | 0406-9910-03 | 30 CAPSULE in 1 BOTTLE (0406-9910-03) | 1977-08-01 |
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013 | NDA | SpecGx LLC | 0406-9911-03 | 30 CAPSULE in 1 BOTTLE (0406-9911-03) | 1977-08-01 |
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013 | NDA | SpecGx LLC | 0406-9912-03 | 30 CAPSULE in 1 BOTTLE (0406-9912-03) | 1977-08-01 |
| Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013 | NDA | SpecGx LLC | 0406-9913-03 | 30 CAPSULE in 1 BOTTLE (0406-9913-03) | 1977-08-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Pamelor
Introduction
Pamelor, the brand name for nortriptyline, is a tricyclic antidepressant predominantly used to treat major depressive disorder, chronic pain, and certain anxiety disorders. Since its initial FDA approval in the late 20th century, Pamelor has become a widely prescribed medication. Its production and distribution involve a network of manufacturers, distributors, and suppliers globally. This report provides a comprehensive overview of the key suppliers associated with Pamelor, examining their roles, market positions, and influences on the drug’s availability.
Overview of Pamelor (Nortriptyline) Manufacturing
The original patent for nortriptyline was held by Merck & Co., which developed Pamelor in the 1960s. Once the patent expired, generic manufacturers entered the market, expanding access and diversifying the supplier base. The current landscape features both brand-name and generic producers, with the latter dominating due to cost advantages and widespread prescribing.
Major Suppliers and Manufacturers
1. Eli Lilly and Company
Eli Lilly originally commercialized Pamelor under the brand name in the late 20th century. Although the patent has expired, Lilly maintains rights to its original formulation and may supply existing stock for specific markets or formulations. The company’s global manufacturing capabilities ensure supply continuity, especially in regions where brand protection persists.
2. Generic Pharmaceutical Manufacturers
Following patent expiration, numerous generic companies began producing nortriptyline. Their roles involve manufacturing, quality assurance, and distribution. Some prominent players include:
-
Teva Pharmaceutical Industries Ltd.
One of the world's largest generic drug producers, Teva offers various formulations of nortriptyline. Its extensive network and production scale contribute significantly to global supply stability. -
Sandoz (Novartis)
Sandoz supplies generic nortriptyline through its global subsidiaries, emphasizing high-quality manufacturing standards and quality assurance protocols. -
Mylan (now part of Viatris)
Mylan’s generic production of nortriptyline expands access across many markets, leveraging its large distribution network. -
Medicines for Europe
Numerous smaller European generics manufacturers also contribute to the supply chain, especially in countries with stringent regulatory standards.
3. Contract Manufacturing Organizations (CMOs)
Some pharmaceutical companies contract CMOs to produce nortriptyline formulations. These organizations—such as Patheon (a part of Thermo Fisher Scientific)—provide manufacturing services to multiple brand and generic companies, ensuring supply flexibility and adherence to quality standards.
4. Distributors and Wholesalers
Distribution firms such as McKesson, Cardinal Health, and AmerisourceBergen play crucial roles in the supply chain, sourcing products from manufacturers and ensuring their delivery through pharmacy and hospital networks across the United States and internationally.
Regional Suppliers and Market Dynamics
United States
In the U.S., the supply of Pamelor relies heavily on generic manufacturers due to the drug’s patent expiration. The FDA's Orange Book lists multiple approved generic versions, with Teva, Mylan, and Sandoz among the primary suppliers. Market competition among generics maintains affordability and steady supply.
Europe and Asia
European markets see active participation from companies like Zentiva and Accord Healthcare. Asian markets involve local manufacturers that produce both generic nortriptyline and formulations under licensing agreements with Western firms. Regulatory standards and patent laws influence supplier diversity regionally.
Emerging Markets
In developing countries, local pharmaceutical companies often produce generic versions of nortriptyline under national regulatory approval pathways, increasing supply options but raising concerns about quality control.
Supply Chain Challenges and Considerations
Regulatory Compliance
Manufacturers must meet stringent standards set by the FDA, EMA, and other regulators, ensuring quality and safety. Non-compliance can lead to recalls and supply disruptions.
Patent and Intellectual Property Rights
While Pamelor’s patent has expired globally, market exclusivity or patent litigations in specific jurisdictions can impact supplier dynamics temporarily.
Production Capacity Constraints
Global shortages occasionally occur due to manufacturing issues, raw material shortages, or regulatory delays, affecting supply continuity.
Pricing and Market Competition
Intense competition among generic suppliers sustains affordable prices but also prompts manufacturers to optimize costs, potentially affecting production investments and inventory levels.
Key Suppliers Summary
| Supplier | Role | Market Presence | Notable Attributes |
|---|---|---|---|
| Eli Lilly | Original brand manufacturer | Limited (brand only) | Maintains manufacturing rights for Pamelor in certain regions |
| Teva | Global generics manufacturer | Extensive | Large-scale production, OEM capabilities |
| Sandoz (Novartis) | Generic producer, part of Novartis | Global | Emphasizes quality assurance |
| Mylan (Viatris) | Generics leader | Global | Wide distribution network |
| Contract CMOs | Manufacturing services for multiple firms | Variable | Flexibility in production capacity |
| Distributors | Logistics and wholesale supply chain | U.S. and global | Critical for maintaining market availability |
Future Outlook
As demand for antidepressant therapy persists, the supplier landscape for Pamelor remains stable, primarily driven by generic producers with high manufacturing capacity and regulatory compliance. Ongoing consolidation among generics firms and advances in manufacturing technology could further enhance supply stability and reduce costs. However, geopolitical and regulatory uncertainties pose potential risks, necessitating continuous monitoring.
Key Takeaways
-
Market Dominance of Generics: The expiration of Pamelor’s patent facilitated a shift towards multiple generic manufacturers, notably Teva, Sandoz, and Mylan, ensuring broad accessibility.
-
Supply Chain Resilience: Diverse regional suppliers and CMOs bolster supply security, though manufacturing disruptions can still impact availability.
-
Regulatory Compliance: Strict adherence to quality standards from authorities like the FDA and EMA remains crucial for uninterrupted supply.
-
Regional Variability: Market penetration and supplier diversity vary regionally, influenced by patent laws, regulatory environments, and local manufacturing capacity.
-
Future Stability: The current supplier network supports consistent Pamelor availability; however, ongoing market and regulatory developments require vigilance.
FAQs
1. Who are the main suppliers of generic nortriptyline today?
The leading suppliers include Teva, Sandoz (Novartis), Mylan (Viatris), and various regional manufacturers, collectively ensuring a stable supply worldwide.
2. Is Eli Lilly still involved in supplying Pamelor?
Eli Lilly originally developed Pamelor but primarily maintains rights to its brand formulation. Most market supply now comes from generic manufacturers, though Lilly may continue limited distribution in select regions.
3. How do supply chain disruptions affect Pamelor availability?
Production issues at manufacturing sites, raw material shortages, or regulatory delays can cause temporary shortages, but the diversified supplier base mitigates long-term disruptions.
4. Are there significant regional differences in Pamelor suppliers?
Yes. In the U.S. and Europe, major generics dominate, while in emerging markets, local manufacturers and licensees provide additional sources, with variability based on local regulation and market demand.
5. What is the outlook for Pamelor’s future supply chain?
The supply chain remains robust due to intense competition among generic producers and flexible manufacturing. Continued regulatory oversight and market dynamics will shape stability moving forward.
References
[1] FDA Orange Book, "Approved Drug Products with Therapeutic Equivalence Evaluations."
[2] European Medicines Agency, "Community Register of Products."
[3] Market intelligence reports from IQVIA and EvaluatePharma on antidepressant markets.
[4] Company reports and websites of Teva, Sandoz, Mylan, and others.
[5] Industry analyses on pharmaceutical manufacturing capabilities and supply chain resilience.
Note: This report reflects the most recent available information as of 2023 and is intended for informational purposes to assist healthcare and business professionals.
More… ↓
